The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.

The global Alzheimer's Therapeutics Market is projected to surpass $6.0 billion in 2026, driven by rising disease prevalence and demand for disease-modifying therapies. Real-world evidence from lecanemab treatment shows strong patient continuation rates, supporting longer treatment durations. Market growth is fueled by increasing R&D investments and M&A activity, though challenges include skilled professional shortages and geopolitical risks from trade tariffs.

Biogen announced that Dr. Maria C. Freire has been elected as the new Chair of the Board of Directors, effective after the company's 2026 Annual Meeting on June 9, 2026. She will succeed Caroline Dorsa, who is retiring after 16 years on the board. Dr. Freire, who joined Biogen's board in 2021, brings extensive experience in biomedical innovation, drug development, and science policy. The leadership transition occurs as Biogen enters a catalyst-rich period with multiple clinical readouts expected in the next 18 months.

Philip Morris International significantly exceeded earnings expectations with EPS of $7.54 vs. $1.70 expected and revenue of $10.4B vs. $10.39B expected, driven by strong growth in smoke-free products. Biogen also beat estimates with EPS of $1.99 vs. $1.61 expected, boosted by strong sales of LEQEMBI and SKYCLARYS. Centene reported mixed results but beat both EPS and revenue expectations. All three companies provided positive 2026 guidance.

Biogen reported Q4 2025 revenues of $2.28 billion, beating consensus estimates, driven by strong growth in Alzheimer's drug Leqembi with in-market sales up 54% to $134 million. The company's newer growth products offset declines in multiple sclerosis drugs. Biogen issued 2026 EPS guidance of $15.25-$16.25, above consensus, and the stock reached a new 52-week high, rising 4.28% to $193.29.

The FDA has accepted for Priority Review a supplemental application for LEQEMBI IQLIK, a subcutaneous autoinjector formulation of lecanemab for early Alzheimer's disease treatment. If approved by May 24, 2026, it would be the first anti-amyloid treatment offering at-home injection options for both treatment initiation and maintenance, potentially reducing healthcare resource requirements associated with intravenous dosing.

The global postpartum depression drugs market is projected to grow from USD 959.62 million in 2025 to USD 1.97 billion by 2033, with a CAGR of 9.45%. Growth is driven by increased awareness of maternal mental health, fast-acting drug development, and reduced stigma. The U.S. dominates with a 40.6% market share, while Asia Pacific is the fastest-growing region. Regulatory delays pose challenges to market expansion.

The article highlights three biotech stocks with significant growth potential in 2026: Eli Lilly (LLY), a leader in the GLP-1 market for obesity and diabetes treatments; Viking Therapeutics (VKTX), developing competitive GLP-1 drugs with potential takeover prospects; and Biogen (BIIB), focused on neurodegenerative disease treatments. Despite biotech sector risks, these companies offer substantial upside opportunities through drug approvals and market expansion.

C4 Therapeutics announced strategic milestones through 2028 for advancing cemsidomide, an investigational IKZF1/3 degrader for multiple myeloma. The company plans to initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b combination trial with elranatamab in Q2 2026, with a recommended Phase 2 dose of 100 µg. Phase 1 data showed 53% overall response rate at the highest dose. The company also outlined a new discovery strategy targeting inflammation and neurodegenerative diseases, with cash runway extending through end of 2028.

The systemic lupus erythematosus (SLE) market is projected to grow at a CAGR of 9.4% from 2025-2034, driven by rising disease prevalence, increased diagnostic awareness, and a robust pipeline of targeted therapies. The US market was valued at USD 2.8 billion in 2024 with approximately 529K diagnosed cases. Currently, only two FDA-approved therapies exist (BENLYSTA and SAPHNELO), but several promising drugs in mid-to-late stage development are expected to reshape the treatment landscape and address significant unmet medical needs.

Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.

Eisai and Biogen announced that China's NMPA has accepted their Biologics License Application for a subcutaneous autoinjector formulation of LEQEMBI (lecanemab), an anti-amyloid beta antibody for early Alzheimer's disease treatment. If approved, this would be the first anti-amyloid treatment in China offering at-home injection from treatment initiation, potentially reducing healthcare resource requirements compared to intravenous administration.